Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00019-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Dongshuo Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Oxidative Phosphorylation, Antitubercular Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Health Commission, National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Mycobacterium tuberculosis in both replicating and non-replicating states relies on oxidative phosphorylation (OxPhos) to generate ATP for its growth and survival. Our research delved into the efficacy of novel regimens targeting the OxPhos pathway in murine models. The combination of bedaquiline, clofazimine, pyrazinamide, alongside telacebec, and SQ109 was investigated against both wild-type M. tuberculosis H37Rv and an Rv0678 mutant with cross-resistance between bedaquiline and clofazimine. The results demonstrated that the combination regimens, particularly bedaquiline + clofazimine + pyrazinamide (BCZ) along with telacebec (BCZT) and SQ109 (BCZS), exhibit significantly enhanced bactericidal activity compared to bedaquiline alone and sterilizing potential against M. tuberculosis in vivo . Notably, the BCZT regimen showed superior activity compared to other treatment regimens in Rv0678 mutant-infected BALB/c mice. The addition of T to BCZ prevented the amplification of bedaquiline-resistant mutants and reduced the number of mice relapsing. Our finding underscores the potential of targeting the OxPhos pathway to combat M. tuberculosis , paving the way for innovative approaches in tuberculosis therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
- Department of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
ORCID-Profile: Eric Nuermberger, Yu Lu, Jian Xu
Förderung
- Beijing Municipal Health Commission
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
- Beijing Hospital Authority
Zitieren
APA
Li, D., Li, L., Zhang, Y., Cheng, K., Liang, W., Nuermberger, E., Qi, X., Fu, L., Wang, B., Yan, C., Xu, R., Lu, Y., & Xu, J. (2025). Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00019-25
Vancouver
Li D, Li L, Zhang Y, Cheng K, Liang W, Nuermberger E, et al. Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00019-25
BibTeX
@article{Li2025,
author = {Li, Dongshuo and Li, Liang and Zhang, Ye and Cheng, Kai and Liang, Wenwen and Nuermberger, Eric and Qi, Xianglong and Fu, Lei and Wang, Bin and Yan, Chenxia and Xu, Rui and Lu, Yu and Xu, Jian},
title = {Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00019-25}
}
EUVIMED